Abstract
Background:Venous thromboembolism (VTE) is a potentially preventable cause of death in people with lung cancer. Identification of those most at risk and high-risk periods may provide the opportunity for better targeted intervention.Methods:We conducted a cohort study using the Clinical Practice Research Datalink linked to Hospital Episode Statistics and Cancer Registry data. Our cohort comprises 10 598 people with lung cancer diagnosed between 1997 and 2006 with follow-up continuing to the end of 2010. Cox regression analysis was performed to determine which demographic, tumour and treatment-related factors (time-varying effects of chemotherapy and surgery) independently affected VTE risk. We also determined the effect of a VTE diagnosis on the survival of people with lung cancer.Results:People with lung cancer had an overall VTE incidence of 39.2 per 1000 person-years (95% confidence interval (CI), 35.4–43.5), though rates varied depending on the patient group and treatment course. Independent factors associated with increased VTE risk were metastatic disease (hazard ratio (HR)=1.9, CI 1.2–3.0 vs local disease); adenocarcinoma subtype (HR=2.0, CI 1.5–2.7, vs squamous cell; chemotherapy administration (HR=2.1, CI 1.4–3.0 vs outside chemotherapy courses); and diagnosis via emergency hospital admission (HR=1.7, CI 1.2–2.3 vs other routes to diagnosis). Patients with VTE had an approximately 50% higher risk of mortality than those without VTE.Conclusions:People with lung cancer have especially high risk of VTE if they have advanced disease, adenocarcinoma or are undergoing chemotherapy. The presence of VTE is an independent risk factor for death.
Highlights
Venous thromboembolism (VTE) is a potentially preventable cause of death in people with lung cancer
People with lung cancer had an overall VTE incidence of 39.2 per 1000 person-years (95% confidence interval (CI), 35.4–43.5), though rates varied depending on the patient group and treatment course
Independent factors associated with increased VTE risk were metastatic disease (hazard ratio (HR) 1⁄4 1.9, CI 1.2–3.0 vs local disease); adenocarcinoma subtype (HR 1⁄4 2.0, CI 1.5–2.7, vs squamous cell; chemotherapy administration (HR 1⁄4 2.1, CI 1.4–3.0 vs outside chemotherapy courses); and diagnosis via emergency hospital admission (HR 1⁄4 1.7, CI 1.2–2.3 vs other routes to diagnosis)
Summary
We conducted a cohort study using the Clinical Practice Research Datalink linked to Hospital Episode Statistics and Cancer Registry data. Cox regression analysis was performed to determine which demographic, tumour and treatmentrelated factors (time-varying effects of chemotherapy and surgery) independently affected VTE risk. We determined the effect of a VTE diagnosis on the survival of people with lung cancer. Our cohort comprises data from four linked healthcare sources: The Clinical Practice Research Datalink (CPRD), Hospital Episodes Statistics (HES), the National Cancer Data Repository (NCDR) and Office for National Statistics (ONS) death certificate data. We selected all patients who had a first lung cancer diagnosis (ICD-10 code C50) between 1 April 1997 and 31 December 2006 (the period from which cancer registry data linked to the CPRD were available). Platelet count was categorised into ‘low’ (o140 Â 106 ml À 1), ‘normal range’ (140– 400 Â 106 ml À 1) and ‘high’ (4400 Â 106 ml À 1)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
